Divi's Lab. (DIVISLAB)

FairStock Score: 47/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• Strong ROCE of 20.4% showing efficient capital utilization
• Established market leader in pharmaceutical contract manufacturing
• Decent sales growth of 12.3% indicating business expansion

Concerns

• Extremely high P/E of 67.2 suggesting overvaluation
• Profit growth of 8.2% lagging behind sales growth indicating margin pressure
• Very low DhanIQ Score of 2/10 reflecting weak fundamentals

AI Analysis

Divi's Lab. is a Stalwart company — a pharmaceutical giant with a market cap of Rs 1.7 lakh crores trading at Rs 6,400 per share. However, the data indicates some challenging dynamics at play. The company's P/E ratio of 67.2 is significantly elevated, suggesting investors are paying a premium price for each rupee of earnings. This is concerning when compared to typical pharmaceutical industry norms. While the company demonstrates solid operational efficiency with a ROCE of 20.4%, indicating management generates good returns on invested capital, the growth trajectory tells a mixed story. Sales growth of 12.3% outpaces profit growth of 8.2%, which suggests margin pressure. The dividend yield of just 0.5% indicates the company retains most profits for reinvestment rather than rewarding shareholders directly. Most notably, the DhanIQ Score of 2 out of 10 signals weak overall fundamentals. Analysis suggests that despite Divi's Lab's established market position in pharmaceuticals, the current valuation appears stretched relative to its growth delivery. The disconnect between the high P/E multiple and modest profit growth raises questions about whether the stock price has run ahead of business fundamentals, making it a complex consideration for investors seeking value.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer